Of all the communities touched by the COVID-19 pandemic, healthcare professionals (HCPs) are arguably among those most affected. Specialists on the front lines in primary care, critical care, infectious diseases, and pulmonology roles have experienced COVID-19 first hand—often risking their own health and that of their families to help. A new report from Apollo Intelligence provides a barometer on physicians’ sentiments for 2022, and together with other research, frames a wake-up call to medical device and pharma teams in charge of building a brand presence with prescribers.

Moderna is broadening the company’s vaccine horizons once again using mRNA technology, widely known for its use in COVID-19 vaccinations. Moderna announced two new vaccine development programs targeting a variety of viruses. 

With COVID-19 cases still high nationwide, “now is not the moment” to drop mask mandates in schools and other public places, U.S. Centers for Disease Control and Prevention (CDC) Director Dr. Rochelle Walensky told Reuters on February 8.

The U.S. Food and Drug Administration added another warning to the regulatory agency’s fact sheet for Johnson & Johnson’s COVID-19 vaccine. In other news, as the Omicron variant rips through the United States, top health officials have noted that the variant is so contagious that if you come into contact with it, you are likely to catch it.

The U.S. Food and Drug Administration approved Pfizer’s tick-borne encephalitis vaccine TICOVAC to prevent TBE in people aged 1 year and older.

Covid-19 probably can be eradicated globally, just like polio, according to research just published in BMJ Global Health. That assumes, however, that a high rate of vaccination occurs globally and that there is a quick response to emerging variants.

The United States Food and Drug Administration approved Bayer’s Lampit (nifurtimox) for use in pediatric patients for the treatment of Chagas disease caused by Trypanosoma cruzi.

The U.S. FDA gave Sanofi SA’s dengue vaccine Dengvaxia a very narrow approval as the company continues to suffer from evidence that its vaccine can cause severe infections in some people.

Novartis announced a five-year commitment in the fight against malaria. The Swiss-based company will invest more than $100 million to advance research and the development of “next-generation treatments” to combat emerging resistance to artemisinin and other currently used antimalarials.

French drugmaker Sanofi said on Monday that new data analyses published in the New England Journal of Medicine confirmed that its vaccine candidate against dengue protected two-thirds of the participants in two late-stage studies. Protection against severe dengue reached 93 percent, while prevention of hospitalization due to the disease reached 80 percent in the volunteers, […]